Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1
Go back to Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1| Merck & Co. (NYSE: MRK) | Delayed: 150.33 -2.01 (1.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $152.34 | 52 Week High | $65.46 | |||
| Open | $150.83 | 52 Week Low | $47.97 | |||
| Day High | $152.22 | P/E | 102.27 | |||
| Day Low | $150.09 | EPS | $1.47 | |||
| Volume | 4,397,470 | |||||
